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Abstract 
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Several risk factors such as 
smoking, air pollution, inhaled toxins, high body mass index and infectious agents are involved in the pathogenesis of 
IPF. In the present study, this meta-analysis study investigates the prevalence of viral and bacterial infections in the IPF 
patients and any possible association between these infections with pathogenesis of IPF.
Methods: The authors carried out this systematic literature review from different reliable databases such as PubMed, 
ISI Web of Science, Scopus and Google Scholar to December 2020.Keywords used were the following “Idiopathic 
pulmonary fibrosis”, “Infection”, “Bacterial Infection” and “Viral Infection”, alone or combined together with the Boolean 
operators "OR”, “AND” and “NOT” in the Title/Abstract/Keywords field. Pooled proportion and its 95% CI were used to 
assess the prevalence of viral and bacterial infections in the IPF patients.
Results: In this systematic review and meta-analyses, 32 studies were selected based on the exclusion/inclusion cri-
teria. Geographical distribution of included studies was: eight studies in American people, 8; in European people, 15 in 
Asians, and one in Africans. The pooled prevalence for viral and bacterial infections w ere 53.72% (95% CI 38.1–69.1%) 
and 31.21% (95% CI 19.9–43.7%), respectively. The highest and lowest prevalence of viral infections was HSV (77.7% 
95% CI 38.48–99.32%), EBV (72.02%, 95% CI 44.65–90.79%) and Influenza A (7.3%, 95% CI 2.66–42.45%), respectively. 
Whereas the highest and lowest prevalence in bacterial infections were related to Streptococcus sp. (99.49%, 95% CI 
96.44–99.9%) and Raoultella (1.2%, 95% CI 0.2–3.08%), respectively.
Conclusions: The results of this review were confirmed that the presence of viral and bacterial infections are the 
risk factors in the pathogenesis of IPF. In further analyses, which have never been shown in the previous studies, we 
revealed the geographic variations in the association strengths and emphasized other methodological parameters 
(e.g., detection method). Also, our study supports the hypothesis that respiratory infection could play a key role in the 
pathogenesis of IP.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic progres-
sive lung disease of unknown etiology. IPF causes pro-
gressive scar tissue which gets worse over time resulting 
in acute dyspnea [1, 2]. Alveolar epithelial injury in IPF 
leads to fibroproliferation, myofibroblast differentiation 
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and excessive collagen and extracellular matrix deposi-
tion, causing impairment of gas exchange, respiratory 
failure and death [3].
The prevalence of IPF is 14–27.9 and 1.25–23.4 cases 
per 100,000 population in the USA and Europe, respec-
tively [4]. The attributable risk of IPF-related morbidity 
and mortality is associated with aging and occurs more 
among males than female [1, 4]. Several risk factors are 
involved in the IPF pathogenesis such as; smoking, high 
body mass index, toxins (inhaled) and infectious disease 
[3]. More recently, numerous studies have demonstrated 
the role of viruses and bacteria in the pathogenesis of 
IPF. It has been shown that patients with IPF have an 
increased bacterial load in bronchoalveolar lavage (BAL) 
fluid compared to healthy people or chronic obstructive 
pulmonary disease (COPD) patients [5–8]. Furthermore, 
various viruses and bacteria has been studied in the 
pathogenesis of IPF, including Respiratory syncytial virus 
(RSV), Parainfluenza virus (PIV), Rhinovirus, Coronavi-
rus, Cytomegalovirus (CMV), Influenza virus, Strepoco-
ccus, Haemophillus and Neisseria [6, 9–11]. It has been 
reported that inflammation plays a critical role in genesis 
and progression of IPF in both human and murine mod-
els, indicating that viral and bacterial infections can be 
led to chronic infection and inflammation that maybe are 
the cause of IPF [12, 13].
Although several studies have been conducted to deter-
mine the prevalence of viral and bacterial infection in the 
IPF patients, the association between IPF pathogenesis 
and viral/bacterial infection remains the subject of ongo-
ing investigation. This meta-analysis study investigates 
the prevalence of viral and bacterial infections in the 
IPF patients and any possible association between these 
infections with pathogenesis of IPF.
Methods
Search strategies
In this meta-analysis, a systematic search was conducted 
for previous studies relevant (2020) reliable databases, 
ISI Web of Science, PubMed, and Scopus. Literature 
searches were carried out by using the following key-
words “Idiopathic pulmonary fibrosis”, “Infection”, “Bac-
terial Infection” and “Viral Infection”, alone or combined 
together with the Boolean operators "OR”, “AND” and 
“NOT” in the Title/Abstract/Keywords field. It should be 
noted that unpublished studies were not included, and 
duplicate ones were removed. Our literature searches 
were conducted by three reviewers independently and 
the search results were compared to prevent having miss-
ing data. Also, we screened citations of collected papers 
to identify additional eligible studies. Titles, abstracts and 
keywords field of all papers were screened, and unrelated 
studies were excluded to increase of specificity in the 
search results. This study was registered in PROSPRO 
(ID: 170736).
Inclusion and exclusion criteria
The inclusion criteria for eligible publications were 
defined as: all research that
• Published: 1990 to 2020.
• Reporting the presence of viral or/and bacterial 
infections [previous (colonization) and/or new infec-
tion] in IPF patients.
• Conducting valid laboratory techniques such as: 
molecular technique, culture, and serology.
• Selecting the proper sampling method including: 
NPS, OPS, Sputum, Serum, Blood, BAL and Lung 
Biopsy.
The exclusion criteria: all research that
• Providing incomplete data or failed presented data 
clearly.
• Animal models-based research.
• Had other infectious agents.
• Overlapping subjects, time, and place of sample col-
lection.
Data extraction and quality assessment
Data extraction was conducted by two authors separately 
and independently based on author’s name, year of pub-
lication, total sample size, number of bacterial and viral 
infections patients, country, types of bacteria, types of 
viruses, types of samples and detection methods. Individ-
ual data from each included study were used in this meta-
analysis. Extracted data were compared and rechecked by 
the first and corresponding authors. The methodological 
quality of the included studies was evaluated using the 
STROBE checklist. A maximum quality evaluation score 
of 32 was considered and articles with scores below 18 
were excluded from this study [14].
Statistical methods
Pooled proportion and its 95% CI were used to assess 
the prevalence of viral and bacterial infections in the IPF 
patients. Generalized linear mixed and random intercept 
logistic regression models were used for pooling preva-
lence [15]. The heterogeneity of proportions between 
included studies was tested and quantified by using 
Cochran’s Q test, Tau^2 and I2, respectively [16, 17]. The 
maximum-likelihood estimator was employed to esti-
mate Tau^2. Logit transformation and Clopper-Pearson 
were used for pooled proportion and confidence interval 
in the individual studies. Also, continuity correction of 
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0.5 in studies with zero cell frequencies [18]. The pooled 
proportion, as an overall prevalence of viral and bacterial 
infections in IPF patients was derived by a random effects 
model because of significantly heterogeneity between 
the individual studies. However, influence analyses was 
performed by the Baujat plot which is a diagnostic plot 
to detect studies contributing to the heterogeneity of a 
meta-analysis [19]. A funnel plot was conducted to detect 
publication bias (logit transformed proportions against 
standard error). Publication bias was tested by Egger’s 
linear regression and Begg’s tests as it was described 
(P < 0.05 was considered statistically significance for pub-
lication bias) [20]. Finally, the sub-group analyses were 
used by types of virus and bacteria, year of publication, 
and country. Meta-regression was applied for assessing 
the effect of age on the pooled prevalence. All of statis-
tical analyses were performed by using “metafor" and 
“meta” R packages.
Results
Search results and studies characteristics
The process of research selection shown in Fig.  1 was 
designed according to Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses. In the initial search, 
2813 articles were identified from ISI Web of Science, 
PubMed, Scopus and Google scholar databases. Based on 
the exclusion/inclusion criteria, 32 studies were included 
in the final meta-analysis. Geographical distribution of 
included studies was; eight studies in America, eight in 
Europe, 15 in Asia, and one in Africa. These studies were 
published from 1992 to 2020 (Table 1).
Quality assessment
Based on the results of the STROBE checklist, high-
est and lowest score were related to Dworniczak et  al. 
(score = 18) and Keyvani et  al. (score = 31), respectively. 
The mean score of STROBE tool for all of included stud-
ies was 25.8 (SD = 4.3, range = 18–31). (Table 1).
Pooled prevalence of viral and bacterial infections 
in the IPF patients
The total number of the IPF patients included in the 
study was 2203 individuals aged 26–87 years based on the 
results of the 32 included studies. The pooled prevalence 
of viral and bacterial infections in the studied patients 
was 57.3% (95% CI 37.91–74.75%) according to a ran-
dom effects meta-analysis. The Wald test showed a sig-
nificant heterogeneity of prevalence between the studies 
(Q statistic = 460; Wald test p-value < 0.001; I^2 = 96.5%; 
τ^2 = 4.69) (Fig. 2). The pooled prevalence for viral infec-
tions was 53.72% (95% CI 38.1–69.1%) according to a ran-
dom effects meta-analysis. While the pooled prevalence 
for bacterial infections was 31.21% (95% CI 19.9–43.7%) 
according to a random effects meta-analysis. There was a 
significant difference of pooled prevalence between viral 
and bacterial infections (P-value < 0.001).
Sub‑group analysis and meta‑regression
The highest and lowest prevalence of viral infections that 
was reported in patients with IPF as follows; HSV (77.7% 
95% CI 38.48–99.32%), EBV (72.02%, 95% CI 44.65–
90.79%) and Influenza A (7.3%, 95% CI 2.66–42.45%), 
respectively (Table  2). Whereas the highest and lowest 
of this prevalence in bacterial infections were related 
to Streptococcus sp. (99.49%, 95% CI 96.44–99.9%) and 
Raoultella (1.2%, 95% CI 0.2–3.08%), respectively. More 
details about heterogeneity test and publication bias is 
shown in Table  2. Also, lowest prevalence of viral and 
bacterial infections was observed in the studies that were 
published from 2013 to 2020 (32%, 95% CI 15–56%) and 
the highest of this prevalence related to the studies pub-
lished between 1999 and 2006 (78%, 95% CI 50–93%). 
The difference of pooled prevalence between the ranges 
of year of publication was significant (P-value < 0.001) 
(Fig.  3). In sub-group analysis based on country, the 
highest prevalence of viral and bacterial infections was 
observed in United States (86.9%, 95% CI 65.7–100%) and 
Japan (69.9%, 95% CI 58.9–78.3%), whereas United King-
dom (5%, 95% CI 2–8.1%) and South Korea (1.5%, 95% CI 
0.4–2.6%) showed the lowest prevalence. Based on the 
meta-regression, with increasing age of the patients, this 
prevalence was significantly decreased (P-value = 0.048) 
(Fig.  4). Sub-group analysis based on the type of detec-
tion methods showed that PCR technique detected 
the highest viral infections in IPF patents (76.4%, 95% 
CI 60.18–90.01%), while using ELISA method showed 
the lowest prevalence of viral infections (32%, 95% CI 
16.1–51.9%). These results for types of detection meth-
ods of bacterial infections indicated the highest and low-
est prevalence observed in the IPF patients related to 
sputum culture (60.2%, 95% CI 27.8–92.4%) and ELISA 
(20.2%, 95% CI 3.3–44.7%) detection methods. In addi-
tion, the highest and lowest prevalence of viral and bacte-
rial infections were observed in the IPF patients related 
to serum (64.8%, 95% CI 38.7–80.9%) and lung tissues/or 
lung biopsy (33.7%, 95% CI 17.71–41.98%) sample types, 
respectively.
Publication bias and sensitivity analysis
Publication bias was statistically significant in this meta-
analysis (Begg’s p-value = 0.041, Egger’s p-value = 0.046) 
(Fig. 5). In most of cases in Table 2, the publication bias 
was not significant. Furthermore, the robustness of the 
pooled prevalence was checked by Baujat plot as a plot 
to identify the studies, which overly contributing to the 
heterogeneity of the meta-analysis. However, the studies 
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of Song et  al. in 2011 [21] and Odashima et  al. in 2020 
[22] have most significant influence on the overall results 
(P-value < 0.001) (Fig. 6).
Discussion
IPF is a fatal progressive lung disease that there is no 
effective cure for this except lung transplant for end-stage 
IPF patients [23]. Moreover, the FDA approved drugs are 
Fig. 1 Search flow diagram for 32 studies included in the meta-analysis
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associated with a number of side-effects, which com-
promises their tolerability in IPF patients. Although, the 
cause of IPF is unknown, recent studies have suggested a 
strong impact of viral and bacterial infections in both the 
initiation and progression of IPF may be through aber-
rant innate immunity [1, 5, 6, 9, 12, 13]. These infectious 
agents can play a crucial role in increased inflammation 
and thus in IPF pathogenesis. Viral infection, both lytic 
and latent, can lead to major fibrosis through increased 
expression of viral gene products in structural and 
immune cells in the lung [6, 12, 24]. More recently, a role 
for bacterial infection has been described in the develop-
ment of a rapidly progressive clinical phenotype in IPF [5, 
25, 26]. Therefore, optimum antiviral and antibacterial 
immunity in the lung is vital in the maintenance of lung 
homeostasis and health [5].
Thus far, no systematic review and meta-analysis study 
has been investigated in the prevalence and the role of 
viral and bacterial infections in IPF except an investiga-
tion by Sheng et al. They suggested viral infection as a risk 
Fig. 2 Forest plot of pooled prevalence of viral and bacterial infections in the IPF patients
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factor (OR 3.48; 95% CI, 1.61–7.52), however not statisti-
cally significant relationship was detected between viral 
infection and exacerbation of IPF (OR 0.99; 95% CI 0.47–
2.12). They also demonstrated that some viruses such as 
CMV, Epstein-Barr virus (EBV) and human herpesvirus 
7, and 8 (HHV-7, HHV-8) were associated with IPF as the 
risk factors, while HHV-6 was not associated. Therefore, 
their results indicated that viral infections may involve in 
IPF pathogenesis [27]. In our study, according to a ran-
dom effects meta-analysis, the pooled prevalence for viral 
infections was 53.72% (95% CI 38.1–69.1%) and the high-
est and lowest prevalence of viral infections was related 
to HSV (77.7% 95% CI 38.48–99.32), EBV (72.02%, 95% 
CI 44.65–90.79%) and Influenza A (7.3%, 95% CI 2.66–
42.45), respectively (Table  2). Numerous investigations 
have been conducted on the role of viruses in pathogen-
esis of IPF, suggesting the role of viral infection in exacer-
bations of IPF [28]. Wootton et al. studied the detection 
of viral infection in IPF patients by pan-viral microarray 
analysis. They detected parainfluenza 1.6% (1/60), rhi-
novirus 3.3% (2/60) and coronavirus 1.6% (1/60) [9]. In 
another study, Keyvani et  al. assessed forty IPF patients 
for viral detection and they detected RSV, parainfluenza, 
rhino and corona viruses in 2.5% (1/40), 7.5% (3/40), 10% 
(4/40), 2.5% (1/40) and 0% (0/40) of patients, respectively. 
Their results indicated a significant positive association 
between age and two viruses (rhinovirus and parain-
fluenza) [24]. In the current study, based on the type of 
detection methods of viral infections we indicated that 
the highest and lowest prevalence of viral infections in 
previously published studies on IPF were observed by 
PCR (83.1%, 95% CI 63.75–94.11%) and ELISA (32%, 95% 
CI 16.1–51.9%), respectively. Thus, it can be proposed 
that the type of detection method is important in the 
report of the prevalence of viral infections. Geographi-
cal variations might explain the inconsistent results that 
is present in the studies. In the present investigation, 
we indicated that the highest prevalence of viral and 
Table 2 Subgroup analysis of the pooled prevalence of viral and bacterial infections in the IPF patients





(Begg’s test, P‑value; Egger’s test, 
P‑value)
Effect model
HCV 3 10.35 (2.29–23.23) (83.7%; P-value = 0.002) (Begg’s Test, 0.30; Egger’s test, 0.19) Random
CMV 12 48.09 (19.53–77.35) (98.3%; P-value < 0.001) (Begg’s Test, 0.73; Egger’s test, 0.80) Random
HSV 4 77.7 (38.48–99.32) (94.8%; P-value < 0.001) (Begg’s Test, 0.73; Egger’s test, 0.63) Random
RSV 3 14.43 (2.51–33.77) (85.7%; P-value < 0.001) (Begg’s Test, 0.30; Egger’s test, 0.53) Random
EBV 9 72.02 (44.65–90.79) (91.29%; P-value < 0.001) (Begg’s Test, 0.66; Egger’s test, 0.70) Random
Adenovirus 2 62.6 (1.0–92.4) (98%; P-value < 0.001) (Begg’s Test, 0.03; Egger’s test, 0.17) Random
Influenza A 2 7.3 (2.66–42.45) (96.7%; P-value < 0.001) (Begg’s Test, 0.53; Egger’s test, 0.79) Random
Parainfluenza 3 48.87 (1.0–99.0) (98.6%; P-value < 0.001) (Begg’s Test, 0.01; Egger’s test, 0.13) Random
B19 2 42.09 (31.28–53.29) (0%; P-value = 0.57) (Begg’s Test, 0.99; Egger’s test, 0.58) Fixed
HHV 8 53.69 (24.52–81.54) (95.9%; P-value < 0.001) (Begg’s Test, 0.79; Egger’s test, 0.83) Random
Rhinovirus 2 15.92 (8.83–25.45) (62.4%; P-value = 0.11) (Begg’s Test, 0.73; Egger’s test, 0.57) Fixed
TTV 3 68.05 (8.19–90.9) (91.9%; P-value < 0.001) (Begg’s Test, 0.68; Egger’s test, 0.98) Random





(Begg’s Test, P‑value; Egger’s test, 
P‑value)
Effect model
Mycobacterium tuberculosis 4 3.16 (0.79–7.01) (90.27%; P-value < 0.001) (Begg’s Test, 0.63; Egger’s test, 0.85) Random
Haemophilus influenza 6 8.50 (2.13–18.53) (86%; P-value < 0.001) (Begg’s Test, 0.23; Egger’s test, 0.59) Random
Streptococcus pneumonia 5 6.64 (0.6–18.43) (89.6%; P-value < 0.001) (Begg’s Test, 0.13; Egger’s test, 0.66) Random
Moraxella catarrhalis 3 5.57 (2.34–10.94) (0%; P-value = 0.97) (Begg’s Test, 0.99; Egger’s test, 0.64) Fixed
Pseudomonas aeruginosa 3 2.88 (1.16–5.84) (0%; P-value = 0.41) (Begg’s Test, 0.99; Egger’s test, 0.45) Fixed
Klebsiella pneumonia 3 2.94 (0.05–9.92) (90.6%; P-value < 0.001) (Begg’s Test, 0.29; Egger’s test, 0.71) Random
Streptococcus pneumonia 5 6.64 (0.6–18.43) (89.6%; P-value < 0.001) (Begg’s Test, 0.43; Egger’s test, 0.56) Random
Staphylococcus aureus 3 2.32 (0.02–8.16) (74.3%; P-value = 0.02) (Begg’s Test, 0.08; Egger’s test, 0.29) Random
Escherichia coli 2 10.69 (0.05–35.96) (90.8%; P-value = 0.001) (Begg’s Test, 0.18; Egger’s test, 0.43) Random
Streptococcus sp. 3 99.49 (96.44–99.9) (0%; P-value = 0.90) (Begg’s Test, 0.99; Egger’s test, 0.86) Fixed
Serratia marcescens 2 1.21 (0.22–3.71) (0%; P-value = 0.31) (Begg’s Test, 0.41; Egger’s test, 0.83) Fixed
Raoultella 2 1.20 (0.2–3.08) (0%; P-value = 0.31) (Begg’s Test, 0.41; Egger’s test, 0.83) Fixed




Heterogeneity: I2 = 96%, τ2 = 4.6939, p < 0.01













Heterogeneity: I2 = 95%, τ2 = 3.7354, p < 0.01
Heterogeneity: I2 = 90%, τ2 = 2.9713, p < 0.01
Heterogeneity: I2 = 97%, τ2 = 7.3384, p < 0.01
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Fig. 3 Forest plot of subgroup analysis for the pooled prevalence of viral and bacterial infections in the IPF patients based on the ranges of year of 
publication
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bacterial infections was in Japan (73.1%, 95% CI 69.3–
76.8%) and United States (86.9%, 95% CI 65.7–100%), and 
the lowest prevalence was in United Kingdom (5%, 95% 
CI 2–8.1%) and South Korea (1.5%, 95% CI 0.4–2.6%).
The viral infection (especially respiratory viruses) may 
be involved in increasing of inflammation (chronic), 
resulting in the pathogenesis of IPF [9, 24, 29]. Due to 
the function of lung, it is exposed to airborne viruses 
and there is mounting evidence, which are provided by 
clinical and preclinical studies, to support a mechanistic 
role for pathogens of IPF [28]. Some viruses cause latent 
infections within the alveolar epithelium and under suit-
able conditions, they are reactivated. This issue can be 
proposed reactivation of the virus acts as a second hit 
to the epithelium following exposure to a first injurious 
insult [30]. Some animal studies have shown that viral 
infection lead to enhance lung fibrosis hence cofactor in 
the IPF development [28]. Viral infection induces stress 
in endoplasmic reticulum (ER) and apoptosis in epithelial 
cells which can implicate in the development of both IPF 
and the pulmonary fibrosis [31, 32]. In an investigation, 
have been shown that acute and chronic viral infections 
are different in some aspect of Immunopathogenesis [5, 
9, 12]. Most of the analyzed studies (including viral infec-
tions) in our study were about persistent viruses that 
were probably acquired before the IPF development.
Although, numerous attempts have conducted on 
the role of viruses in the IPF pathogenesis, there are a 
few studies investigating the role of bacteria in this dis-
ease. In a recent study, it was demonstrated that 7.5% of 
IPF patients (BAL sample) were found to be positive in 
bacterial culture, while none of the controls had bacte-
rial infection. The most common bacterial genus were 
Streptococcus (30%) followed by Veillonella (10.6%) and 
Prevotella (10.9%) [6]. In another study, Richter et  al. 
reported 36.3% of stable IPF patients was positive BAL 
cultures and bacterial genus were Pseudomonas, Haemo-
philus and Streptococcus [33]. In our study, the pooled 
prevalence for bacterial infections was 31.21% (95% CI 
19.9–43.7%) according to a random effects meta-analysis. 
In addition, the highest and lowest prevalence in bacte-
rial infections were related to Streptococcus sp. (99.49%, 
95% CI 96.44–99.9%) and Raoultella (1.2%, 95% CI 0.2–
3.08%), respectively. High case fatality rate related to bac-
terial respiratory tract infection in IPF, indicating that 
bacteria are involved in driving IPF disease progression. 
Recently, studies using culture-independent techniques 
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Fig. 4 Trend plot of logit (logarithm of odds ratio between the 
infections and non-infection) of viral and bacterial infections over age 
of the IPF patients (P-value = 0.048)
Fig. 5 Funnel plot to detect publication bias (Begg’s p-value = 0.041, 
Egger’s p-value = 0.046)
Fig. 6 Baujat plot to detect the studies overly contributing to the 
heterogeneity of this meta-analysis
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in IPF patients is associated with an enhanced risk of ear-
lier mortality in IPF [6, 34, 35]. These results for types 
of detection methods of bacterial infections showed the 
highest and lowest prevalence were observed in the IPF 
patients related to sputum culture (60.2% 95% CI 27.8–
92.4%) and ELISA (20.2% 95% CI 3.3–44.7%) detection 
methods. Also, as mentioned earlier our results indi-
cated the prevalence of viral and bacterial infections was 
highest in Japan (73.1%, 95% CI 69.3–76.8%) and United 
States (86.9%, 95% CI 65.7–100%) and this prevalence 
was lowest in United Kingdom (5%, 95% CI 2–8.1%) and 
South Korea (1.5%, 95% CI 0.4–2.6%) countries. Infec-
tious agents induce immune responses that can lead to 
chronic conditions and inflammatory infiltrates, both of 
which have shown too involved in IPF pathogenesis (23). 
Moreover, preclinical and clinical studies demonstrated 
that inflammation is probably involved in initiation and 
progression of IPF (9, 10).
Cytokine patterns in patients with IPF may shed light 
on the predominant cell types pivotal to various stages 
of the disease. Overexpression of Th2 Cytokines includ-
ing IL-4, IL-5, and IL-13 in cellular cultures from patients 
with IPF has been previously reported [13]. A series of 
cytokines (MIP-1α/CCL3), MCP-1/CCL2, and IL-8) 
connected to neutrophil, monocytes, and lymphocyte 
chemotaxis and activation are increased significantly 
in tissue or fluid from the lungs of IPF patients [13, 24]. 
IL-1α and IL-1β are widely expressed cytokines by alveo-
lar macrophages of IPF patients. This expression lead to 
induce a pro-fibrotic phenotype through the synthesis 
of platelet-derived growth factor and procollagen types I 
and III [36]. Tumor necrosis factor alpha (TNF-α), which 
is produced by epithelial cells, endothelial cells, lym-
phocytes and macrophages, upregulates various path-
ways and factors those involved in inflammation such as 
the IL-1, IL-6, growth factor beta (TGF-β), C-X-C motif 
chemokine ligand 8, stimulation of cell–cell adhesion 
and transendothelial migration [37]. The overexpression 
of TGF-β results in modulation of extracellular matrix 
(ECM) productions. This modulation is due to the effects 
of different factors including fibronectin, proteoglycans, 
collagens I, III, IV, V and the inhibition of modifying 
ECM enzymes such as plasminogen and metalloprotein-
ase [38].
All researches that reported the viral and bacterial 
infection in IPF patients were included in this meta-
analysis. The sample size in some researches was small. 
Furthermore, the viral and bacterial infection rates were 
variable due to Variety of geographical locations, viral/
bacterial detection techniques and the sites of biologi-
cal samples or type of samples. Different methods led to 
alterations in sensitivity and specificity. Given these chal-
lenges, larger-scale samples are needed in the future to 
draw conclusions about causal relationship between IPF 
and viral-bacterial infections.
Our study had several limitations; first, the small sam-
ple size, relative wide confidence intervals and study 
were conducted in a single center. Second, the pathogen 
types were specific to the study area. Thus, our results are 
probably not applicable to other patient populations. The 
association between viral infection and acute exacerba-
tion of IPF requires further investigation.
Conclusion
The current study provides the overall viral and bacte-
rial infection prevalence in IPF patients and information 
about circulating types of viruses and bacterial world-
wide. The presence of viral and bacterial infections is a 
risk factor in the pathogenesis of IPF. We revealed the 
geographic variations in the association strengths and 
emphasized other methodological parameters (e.g., 
detection method) in further analyses that have never 
been shown in the previous studies. Also, our study sup-
ports the hypothesis that respiratory infection could play 
a key role in the pathogenesis of IPF.
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